Results 151 to 160 of about 202,243 (244)

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Germline Cancer Predisposition and De Novo Contributions in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Approximately 6%–8% of children and adolescents with rhabdomyosarcoma (RMS) have an underlying cancer predisposition disorder (CPD), which varies between embryonal and alveolar subtypes and other clinical characteristics. Identifying a CPD remains challenging, as traditional approaches rely on clinical features and family history. Additionally,
Taylor M. Luckie   +12 more
wiley   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue   +6 more
wiley   +1 more source

New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours

open access: yes, 2001
Neuroendocrine tumours are frequently malignant and have often reached an advanced stage by the time of diagnosis when they are inoperable, accompanied by severe symptoms, sometimes of an endocrine nature.
Lombardi G.   +7 more
core  

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Hypervision Proton Surgery: The Future Direction of Proton Therapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Neuroendocrine tumours [PDF]

open access: yesPostgraduate Medical Journal, 1995
openaire   +1 more source

High‐Sugar Diet and Intestinal Diseases: A Shared Microbiota–Barrier–Immunity–Metabolism Axis in Inflammatory Bowel Disease, Food Allergy, and Colorectal Cancer

open access: yesiNew Medicine, EarlyView.
ABSTRACT The global incidence of intestinal diseases—including food allergy, inflammatory bowel disease (IBD), and colorectal cancer (CRC)—continues to escalate in parallel with the expansion of the “Western diet,” within which the high‐sugar diet (HSD) has emerged as a pivotal yet under‐recognized dietary driver.
Yuchen Wang   +9 more
wiley   +1 more source

Bidirectional Pathological Axis Between Alzheimer's Disease and Circadian Rhythm Disturbance: Mechanisms and Therapeutic Strategies

open access: yesiNew Medicine, EarlyView.
This graphical abstract illustrates a bidirectional vicious cycle between Alzheimer’s disease (AD) and circadian rhythm disturbance (CRD). On the one hand, AD pathology, including amyloid‐β (Aβ) plaque deposition and tau hyperphosphorylation, may damage the suprachiasmatic nucleus (SCN) and disrupt melatonin signaling, leading to sleep fragmentation ...
Jiajia Qin   +10 more
wiley   +1 more source

Compare Serum VCAM‐1, NSE, Procalcitonin in Predict Sepsis Induced Encephalopathy in Septic Patients

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Serum VCAM‐1 is associated with septic encephalopathy in the first 7 days of sepsis. NSE and procalcitonin were not associated with septic encephalopathy. ABSTRACT Background Sepsis‐associated encephalopathy (SAE) is a common complication of severe sepsis. Increased concentration of Vascular Cell Adhesion Molecule 1 (VCAM‐1) is associated with SAE in a
Chun‐Fu Lin   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy